Insider buying last 90 days
No open-market insider purchases were filed for BRKR in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Bruker closed at $66.54 on 9 November 2026, +8.5% on the day. The price sits above both the 50-day ($59.20) and 200-day ($50.52) moving averages, inside a 52-week range of $32.37 to $68.98. The GekkoIndex reads 50.8, in the Neutral zone, down 10.6 points over five sessions. Gekko Fair Value is $51.10, so the price is 30.2% above it.
The next earnings report is due on 11 February 2027, 88 days away (before open). Over the last 8 reports the company beat the earnings estimate 6 times, with an average move of 9.4% across the report. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged +5.7% over the last 5 years, rising in 3 of them.
8 firms rate the stock: 3 buy, 4 hold and 1 sell, with a consensus target of $63.83. A typical daily move is about 6.4%, and a typical 20-day move about 7%. On the swing-trade checklist, 3 items read supportive and 2 read as a headwind (fair value, smart money).
A plain summary of the figures as of the Nov 9, 2026 close.
Bruker scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $61.59 is above the 50-day ($59.48) and 200-day ($50.82) averages, and the 50-day is above the 200-day.
See the chart57.6, Neutral
Reading 57.6 is in the Neutral zone.
See the GekkoIndex18.9% above
Price is 18.9% above Gekko Fair Value (more than 5% above).
See fair valueLeans bearish
Last 30 days: 1 unusual options signal.
See smart moneyReports in 88 days
Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.
See earnings+5.1% on average
From this point in the calendar, the next 20 trading days averaged +5.1% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Bruker closed at $61.59 on Nov 13, 2026, +45.0% over the past year, inside a 52-week range of $32.37 to $68.98.
Use the left and right arrow keys to read daily values.
Put BRKR on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Bruker designs, builds and sells scientific instruments used for research, analysis and diagnostics. Its offerings span mass spectrometry systems, X-ray equipment, atomic force microscopy tools and optical fluorescence microscopy, along with diagnostic products such as the MALDI Biotyper for pathogen identification, molecular test kits, DNA test strips and PCR-based testing, including solutions developed for SARS-CoV-2 detection.
The business is organized into three segments: Life Science, NANO, and Energy & Supercon Technologies. Life Science covers instruments and diagnostics for research and clinical use, along with products supporting multi-omics work in drug and biomarker discovery. NANO focuses on tools such as X-ray metrology, AFM defect detection, and equipment for photomask repair and cleaning. The Energy segment supplies superconducting materials, including metallic low-temperature superconductors, and related equipment such as synchrotron and beamline instrumentation. Bruker also works with Newomics Inc. on an LC-MS platform aimed at drug discovery.
Bruker was founded in 1991 and is headquartered in Billerica, Massachusetts. Its shares are listed on the NASDAQ under the ticker BRKR.
Bruker’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.6, in the Neutral zone, up 2.9 points over five sessions.
Up 2.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 50 | +3.2% | +0.4% | ||
| Accumulation | 260 | −0.2% | −1.9% | ||
| Neutral (current zone) | 355 | −0.2% | +1.3% | ||
| Distribution | 31 | +1.2% | +3.5% | ||
| Selling | 6 | Too few readings yet | |||
Average BRKR share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Bruker trades 18.9% above Gekko Fair Value of $51.79, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what Bruker shares are worth, recalculated every trading day.
$51.79
Gekko Fair Value, Nov 14, 2026
18.9% Overvalued
At the end of Aug 2026 the price was 17.2% above the estimate.
No open-market insider purchases were filed for Bruker, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BRKR in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in BRKR were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Bruker has been buying back its own shares.
From company filings.
1signal, 22% of the flagged premium in calls.
Latest: Bearish flow on Nov 4, $763K in unusual premium.
2of the funds Gekko tracks hold BRKR.
Bruker reports on Feb 11, 2027, before the open (88 days away), and beat the EPS estimate in 6 of its last 8 reports.
Feb 11, 2027
Expected before the open, 88 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Nov 4, 2026 | $0.56 est $0.42 | $874.0M est $865.2M | +2.8% |
| Aug 4, 2026 | $0.49 est $0.38 | $838.5M est $853.6M | −18.4% |
| May 6, 2026 | $0.31 est $0.23 | $823.4M est $795.6M | +15.0% |
| Feb 12, 2026 | $0.59 est $0.65 | $977.2M est $962.3M | −14.0% |
| Nov 3, 2025 | $0.45 est $0.32 | $860.5M est $964.6M | +3.7% |
| Aug 4, 2025 | $0.32 est $0.33 | $797.4M est $810.2M | −15.6% |
| May 7, 2025 | $0.47 est $0.46 | $801.4M est $819.9M | +2.7% |
| Feb 13, 2025 | $0.76 est $0.74 | $979.6M est $965.6M | −3.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Bruker is $68.00, +10.4% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Guggenheim | $72 | +16.9% |
| Nov 5 | Leerink Partners | $85 | +38.0% |
| Nov 5 | J.P. Morgan | $60 | −2.6% |
| Nov 5 | Citi | $64 | +3.9% |
| Nov 5 | Barclays | $70 | +13.7% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Bruker averaged +5.1% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.5% | 2 of 5 |
| Next 10 trading days | +3.4% | 3 of 5 |
| Next 15 trading days | +3.9% | 3 of 5 |
| Next 20 trading days | +5.1% | 3 of 5 |
| Next 30 trading days | +7.1% | 4 of 5 |
For scale, BRKR’s typical 20-trading-day move in either direction is about 7%.
Bruker’s market cap is $9.41B and revenue of $3.51B over the last twelve months.
Coverage of Bruker this week reads positive: 3 positive, 1 neutral and 0 negative headlines.
Bruker’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| TMOThermo Fisher Scientific | Neutral | 15.0% above |
| ABTAbbott Laboratories | Neutral | 10.5% below |
| DHRDanaher | Neutral | 4.7% above |
| ISRGIntuitive Surgical | Neutral | 17.5% above |
| MDTMedtronic | Neutral | 14.2% below |
| SYKStryker | Neutral | 0.1% below |
A peer links to its own page where one exists.
Bruker’s market cap is $9.41B at the Nov 13, 2026 close of $61.59, with 152.7M shares outstanding.
The consensus analyst 12-month price target for Bruker is $68.00, +10.4% from the last close. Of the 8 firms that rated the stock in the last 90 days, 3 rate it a buy, 4 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Bruker is overvalued: the Nov 13, 2026 close of $61.59 is 18.9% above Gekko Fair Value of $51.79. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Bruker is expected to report on Feb 11, 2027, before the market opens (88 days away). Analysts expect earnings of $0.77 per share on revenue of $1.00B. Bruker beat the earnings estimate in 6 of its last 8 reports, moving 9.4% on average across the report.
Bruker’s 52-week high is $68.98 and its 52-week low is $32.37; it closed at $61.59 on Nov 13, 2026, +45.0% over the past year. Over the last five years the shares peaked at $94.86 on Mar 21, 2024.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (fair value and smart money). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in Bruker over the last 30 days, with $164K of flagged premium in calls and $599K in puts. The latest, bearish flow, was on Nov 4, 2026 with $763K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.